What Recent Market Trends Mean for Aptose Biosciences Inc’s (APTO) Stock

In the past week, APTO stock has gone down by -10.00%, with a monthly decline of -20.44% and a quarterly plunge of -39.50%. The volatility ratio for the week is 10.31%, and the volatility levels for the last 30 days are 9.03% for Aptose Biosciences Inc The simple moving average for the past 20 days is -7.90% for APTO’s stock, with a -51.06% simple moving average for the past 200 days.

Is It Worth Investing in Aptose Biosciences Inc (NASDAQ: APTO) Right Now?

APTO has 36-month beta value of 1.29. Analysts have mixed views on the stock, with 1 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

The public float for APTO is 9.34M, and currently, short sellers hold a 0.54% ratio of that float. The average trading volume of APTO on April 04, 2024 was 93.48K shares.

APTO) stock’s latest price update

Aptose Biosciences Inc (NASDAQ: APTO) has experienced a decline in its stock price by -8.86 compared to its previous closing price of 1.58. However, the company has seen a fall of -10.00% in its stock price over the last five trading days. Seeking Alpha reported 2024-03-26 that Aptose Biosciences Inc. (APTO) Q4 2023 Earnings Call Transcript

Analysts’ Opinion of APTO

Many brokerage firms have already submitted their reports for APTO stocks, with Cantor Fitzgerald repeating the rating for APTO by listing it as a “Overweight.” The predicted price for APTO in the upcoming period, according to Cantor Fitzgerald is $10 based on the research report published on October 19, 2020 of the previous year 2020.

Alliance Global Partners, on the other hand, stated in their research note that they expect to see APTO reach a price target of $12. The rating they have provided for APTO stocks is “Buy” according to the report published on September 22nd, 2020.

Maxim Group gave a rating of “Buy” to APTO, setting the target price at $16 in the report published on February 20th of the previous year.

APTO Trading at -19.92% from the 50-Day Moving Average

After a stumble in the market that brought APTO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -85.23% of loss for the given period.

Volatility was left at 9.03%, however, over the last 30 days, the volatility rate increased by 10.31%, as shares sank -18.18% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -26.90% lower at present.

During the last 5 trading sessions, APTO fell by -10.00%, which changed the moving average for the period of 200-days by -75.55% in comparison to the 20-day moving average, which settled at $1.5475. In addition, Aptose Biosciences Inc saw -43.31% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at APTO starting from Seizinger Bernd R., who purchase 17,000 shares at the price of $3.14 back on Sep 22 ’23. After this action, Seizinger Bernd R. now owns 17,000 shares of Aptose Biosciences Inc, valued at $53,380 using the latest closing price.

Stock Fundamentals for APTO

The total capital return value is set at 23.04. Equity return is now at value -293.96, with -159.98 for asset returns.

Based on Aptose Biosciences Inc (APTO), the company’s capital structure generated -0.54 points at debt to capital in total, while cash flow to debt ratio is standing at -44.27. The debt to equity ratio resting at -0.35. The interest coverage ratio of the stock is 94.86.

Currently, EBITDA for the company is -52.84 million with net debt to EBITDA at 0.16. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.78.

Conclusion

To put it simply, Aptose Biosciences Inc (APTO) has had a bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.

Related Posts